Bio-Gene Technology (ASX:BGT) Total Operating Expense: A$3.44 Mil (TTM As of Dec. 2025)


What is Bio-Gene Technology Total Operating Expense?

Bio-Gene Technology ASX:BGT Total Operating Expense is A$3.44 Mil as of Dec. 2025. The stock has 2 warning signs investors should review.

Bio-Gene Technology's Total Operating Expense for the six months ended in Dec. 2025 was A$1.87 Mil. Bio-Gene Technology's Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 was A$3.44 Mil.

Bio-Gene Technology Total Operating Expense Related Terms

Bio-Gene Technology Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Bio-Gene Technology's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bio-Gene Technology Total Operating Expense Chart

Bio-Gene Technology Annual Data
Trend Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Operating Expense
Get a 7-Day Free Trial 3.04 3.85 3.78 3.12 3.11

Bio-Gene Technology Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.68 1.44 1.54 1.57 1.87

Bio-Gene Technology Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$3.44 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of A$3.44 Mil mean?
Bio-Gene Technology (ASX:BGT) has a Total Operating Expense of A$3.44 Mil as of Dec. 2025. Total operating expense is the primary recurring expense associated with central operations. View historical data on Bio-Gene Technology and its competitors.
Is Bio-Gene Technology's Total Operating Expense too high?
Bio-Gene Technology's current Total Operating Expense is A$3.44 Mil.
How does Bio-Gene Technology's Total Operating Expense compare to VRTX and REGN?
Bio-Gene Technology's Total Operating Expense of A$3.44 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Bio-Gene Technology and its competitors. Bio-Gene Technology's current Total Operating Expense is A$3.44 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Gene Technology stock overvalued right now?
Bio-Gene Technology (ASX:BGT) has a current Total Operating Expense of A$3.44 Mil. The current Total Operating Expense is A$3.44 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Bio-Gene Technology (ASX:BGT), the current Total Operating Expense is A$3.44 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bio-Gene Technology Business Description

Address 400 Collins Street, Level 6, Melbourne, VIC, AUS, 3000
Bio-Gene Technology Ltd is an Australian company developing novel bio-insecticides to address the challenges of insecticide resistance and toxicity. Its products are based on a naturally occurring class of compounds to overcome resistance to control pests with minimal impact on human health and the environment. Bio-Gene's products have multiple applications across public health, crop protection, grain storage, and consumer use. The company operates in one business segment, being the conduct of research and development activities in the discovery of novel insecticides.